Strong growth, innovation, and global reach drive the company’s progress. Read More

Yo-Yo dieting without additional treatment can explain high placebo response rates in NASH clinical trials. Read More

Free access to Simulations Plus software for accredited universities will accelerate learning and educational pursuits. Learn More

“We are very proud and humbled by our achievements at SLP over these past 25 years and look forward to celebrating this milestone over the next year with our clients, employees, and collaborators,” said Shawn O’Connor, CEO. Learn More

Gustavo Mendez Lima Santos Joins Simulations Plus (Formerly Anvisa, Brazil) (11/3/22) Renée Bouché celebrates 21 years at Simulations Plus (10/29/22) Frederico Martins Joins Simulations Plus (Formerly esqLABS, Galapagos Pharmaceuticals, Certara) (10/24/22) Xavier Pepin Joins Simulations Plus (Formerly AstraZeneca & Sanofi) (5/2/22) Anant Ketkar Joins Simulations…

Simulations Plus 25th Anniversary Celebration Concludes with $25,000 Gift to Nonprofit, Girls Who Code (11/3/22)  Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit International Organization for Childhood Cancer (7/21/22) Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit National Organization for Rare…

Improving Health Through Innovative Solutions in Model-Based Drug Discovery. Watch Session Replays

Providing one-on-one support for our clients and partners as they navigate the long and winding road of model-informed drug discovery. Learn More

Simulations Plus and the University of Bath Awarded New FDA Grant (11/15/22) Simulations Plus and the University of Florida Awarded New FDA Contract to Support Development and Regulatory Assessment of Inhaled Products (11/2/22) Simulations Plus Enters New Collaboration to Enhance Machine Learning Models for Ionization…

Simulations Plus Releases GastroPlus® Version 9.8.3 (10/12/22) Simulations Plus Releases State-of-the-Art QSP Software for Interstitial Lung Disease (8/31/22) Simulations Plus Releases ADMET Predictor Version 10.4 (X.4) (5/26/22) Simulations Plus Releases MembranePlus 3.0 (3/10/22) Lixoft Adds New Bioequivalence Module in MonolixSuite® Version 2021R1 (1/5/22)

Expanding access to high-quality medication for people in need Read More

In January 2020, Grace Fraczkiewicz celebrated her 20 years of service with Simulations Plus. Read About Her Journey

In August of 2018, Robert Fraczkiewicz celebrated his 20 years of service with Simulations Plus. Read About His Journey

Simulations Plus hosts the Inaugural 2021 MIDD+ Scientific Conference with over 50 Model-Informed Drug Development Sessions. Read More

Simulations Plus announced underwritten public offering of 2,090,909 shares of its common stock to the public at $55.00 per share. Learn More

Lixoft becomes a wholly owned subsidiary of Simulations Plus on April, 2020. Lixoft is design software solutions based on scientific breakthroughs to reduce the cost and increase the success rate of new drug development. Learn More

Simulations Plus released version 10.0 of its flagship machine learning modeling platform, ADMET Predictor®, The new release is marketed as APX™ on September 2020. Read More

Shawn M. O’Connor appointed as Chief Executive Officer(CEO) effective from June 26, 2018. Learn More

Predictions of ionization constants performed by the S+pKa method implemented in ADMET Predictor™ software wins SAMPL6 pKa challenge on February 2018. Learn More

DILIsym becomes a wholly owned subsidiary of Simulations Plus. DILIsym is the global leader in the simulation of drug-induced liver injury (“DILI”). Learn More